Wednesday, October 31, 2012

Nuclear Medicine: PET Radiopharmaceutical Receives European Endorsement for Imaging of β-Amyloid Density

A European health agency has recommended marketing authorization for Amyvid (florbetapir 18F) as a diagnostic imaging agent in patients who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.

Monday, October 29, 2012

Radiography: 3D CT Breast Cancer Scanning Technology

Newly developed technology provides three-dimensional (3D) X-ray imaging of the breast with a radiation dose that is lower than the current 2D X-ray imaging used in clinics.

Sunday, October 28, 2012

MRI: MRI Proves Effective Guiding Heart Catheter Procedures

Heart catheter procedures guided by magnetic resonance imaging (MRI) are as safe as X-ray-guided procedures and do not take any longer, according to a pilot study.

Thursday, October 25, 2012

Men's Health: Task Force Recommends Against Hormone Replacement Therapy for Postmenopausal Women

The United States Preventive Services Task Force recommends against the use of estrogen and progestin for the prevention of chronic medical conditions in postmenopausal women

Wednesday, October 24, 2012

Imaging IT: New DICOM Guard Technology for high patient Data safety

A new Digital Imaging and Communications in Medicine (DICOM) application features proprietary data tagging technology, which allows healthcare enterprises to have complete control over security of their patient data.

Monday, October 22, 2012

Ultrasound: Collaborative Efforts to Develop Medical Ultrasound Practice Guidelines

American medical societies have collaborated on a guideline that comprises indications for an ultrasound examination for a focused reproductive endocrinology and infertility scan.

Sunday, October 21, 2012

Nuclear Medicine: The specificity and overall accuracy of F-18-FLT were considerably higher than F-18-FDG PET both during and after radiation therapy.

Determining the optimal treatment course and predicting outcomes may soon become simpler for head and neck sqaumous cell carcinomas (HNSCCs) patients with the use of a new investigational imaging agent.